CN113730341A - Bitong gel and using method and preparation method thereof - Google Patents

Bitong gel and using method and preparation method thereof Download PDF

Info

Publication number
CN113730341A
CN113730341A CN202111145139.1A CN202111145139A CN113730341A CN 113730341 A CN113730341 A CN 113730341A CN 202111145139 A CN202111145139 A CN 202111145139A CN 113730341 A CN113730341 A CN 113730341A
Authority
CN
China
Prior art keywords
parts
agent
preparation
gel
raw materials
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111145139.1A
Other languages
Chinese (zh)
Inventor
季顺进
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Haokai Medical Technology Co ltd
Original Assignee
Zhejiang Haokai Medical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Haokai Medical Technology Co ltd filed Critical Zhejiang Haokai Medical Technology Co ltd
Priority to CN202111145139.1A priority Critical patent/CN113730341A/en
Publication of CN113730341A publication Critical patent/CN113730341A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A61K36/195—Strobilanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/268—Asarum (wild ginger)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A61K36/315—Isatis, e.g. Dyer's woad
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/739—Sanguisorba (burnet)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/86—Violaceae (Violet family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The application relates to the field of rhinitis treatment medicines, and particularly discloses a Bitong gel and a using method and a preparation method thereof. The nose-clearing gel comprises an agent A and an agent B; the using method comprises the following steps: first a cycle of treatment with agent a, followed by a cycle of treatment with agent B; the preparation method comprises the following steps: s1, preparation of an agent A; and S2.B agent preparation. The application adopts the A agent and the B agent to carry out administration on a patient in a grading manner, rhinitis is effectively treated through the A agent, the immunity of the patient is improved through the B agent, damaged nasal mucosa is repaired, rhinitis relapse prevention is realized, the better curative effect is achieved, the later-stage relapse prevention is realized, the influence of toxic medicinal materials such as cocklebur fruit in the A agent on a human body is reduced, the toxic and side effects of medication on the patient are reduced, the better enhancement effect is favorably achieved, the physical quality of the patient is improved, the resistance of the patient to other diseases is improved, and the probability of rhinitis relapse caused by other diseases is reduced.

Description

Bitong gel and using method and preparation method thereof
Technical Field
The application relates to the field of rhinitis treatment medicines, in particular to a Bitong gel and a using method and a preparation method thereof.
Background
Rhinitis, which is an inflammatory disease of nasal cavity, is inflammation of nasal mucosa caused by viruses, bacteria, allergens, various physicochemical factors and certain systemic diseases, and the main pathological changes of rhinitis are nasal mucosa congestion, swelling, exudation, hyperplasia, atrophy or necrosis, etc., which are common symptoms of the nose.
The symptoms of rhinitis are mainly manifested as: nasal obstruction and running nose can cause tinnitus and hearing loss, chronic pharyngitis or cough is easy to occur, and long-term nasal cavity ventilation is not smooth, so that memory decline, insomnia, neurasthenia and other complications can be caused.
Most of rhinitis is clinically treated by western medicines or operations, the rhinitis is easy to relapse after treatment, and the rhinitis has large toxic and side effects and is difficult to achieve ideal effects.
Disclosure of Invention
In order to solve the problem of poor treatment effect of rhinitis, the application provides a Bitong gel and a using method and a preparation method thereof.
In a first aspect, the application provides a nasal obstruction gel and a using method thereof, and adopts the following technical scheme:
the nose-clearing gel comprises an agent A and an agent B, wherein the agent A comprises the following raw materials in parts by weight: 5-10 parts of cocklebur fruit, 10-15 parts of centipeda minima, 8-10 parts of biond magnolia flower, 4-6 parts of ligusticum chuanxiong hort, 4-6 parts of angelica dahurica, 1-3 parts of asarum, 6-10 parts of Chinese violet, 10-15 parts of wild chrysanthemum flower, 4-6 parts of borneol, 4-6 parts of menthol, 1-2 parts of musk, 1-2 parts of saffron crocus and 8-10 parts of indigo naturalis;
the agent B comprises the following raw materials in parts by weight: 12-15 parts of garden burnet root, 15-20 parts of Chinese violet, 20-25 parts of cotton rose hibiscus leaf, 10-12 parts of centipeda minima leaf, 8-10 parts of wild chrysanthemum flower, 4-6 parts of ligusticum chuanxiong hort, 4-6 parts of borneol, 4-6 parts of menthol and 1-2 parts of musk;
the application method of the nasal obstruction gel comprises the following steps: applying the A preparation to nasal cavity of patient for a period of treatment; after the treatment of the A preparation is finished, the B preparation is smeared in the nasal cavity of a patient and is treated for one cycle.
By adopting the technical scheme, in the preparation A, the cocklebur fruit, the biond magnolia flower, the dahurian angelica root and the manchurian wildginger are used for freeing nasal orifices, dispelling wind and removing dampness, can effectively treat rhinitis and relieve the symptoms of wind cold of patients, the centipeda minima and the philippine violet herb are anti-inflammatory and antiviral, can inhibit breeding of bacteria and viruses, can relieve nasal obstruction symptoms, inhibit further infection of viruses, the szechuan lovage rhizome, the musk and the saffron have the effects of activating blood circulation to dissipate blood stasis, relieving swelling and pain, relieving congestion, edema symptoms of nasal cavity, facilitating blood circulation in nasal mucosa, relieving nasal inflammation, facilitating discharge of purulent nasal discharge, the wild chrysanthemum and the indigo naturalis used for clearing away heat and toxic materials, cooling blood and relieving blood heat, and can also relieve complications of rhinitis, such as cough, dizziness and the like caused by rhinitis, and the traditional Chinese medicine raw materials are used in a compound mode, and can effectively treat the rhinitis and discharge nasal toxin.
In the preparation B, the garden burnet root detoxifies and heals sore, accelerates the healing of damaged tissues of nasal mucosa, is used for repairing the nasal mucosa, and the Chinese violet is rich in microelements such as copper, iron, manganese, zinc, magnesium and the like, has the effects on the activity of various enzymes in human bodies, has direct or indirect effects on the synthesis of nucleic acid protein, the immune process and cell reproduction, can promote cell repair and cell division, and further promotes the repair of the damaged nasal mucosa.
The centipeda minima leaves can expel wind and clear away cold, build the body, prevent wind cold, diminish inflammation and resist viruses, inhibit bacteria and virus breeding, reduce nasal inflammation, prevent rhinitis recurrence, activate blood circulation and dredge channels of the musk and the cottonrose hibiscus leaves, reduce swelling and relieve pain, cool blood and stop bleeding, prevent nasal mucosa congestion, clear away heat and toxic materials, remove dirt and dissipate blood stasis of the musk, the wild chrysanthemum flower and the cottonrose hibiscus leaves, are favorable for discharging vivotoxin, enhance the immunity of a human body, activate blood and promote qi circulation of the ligusticum chuanxiong hort, dispel wind and relieve pain, and can relieve the irritation of medicaments to the nasal mucosa and discomfort caused by the repair of nasal mucosa tissues.
The herba violae contains acidic substances such as organic acid, tannin and the like, the activity of protein can be influenced by the acidic environment, the cell repair is not facilitated, hydroxyl contained in the molecular structures of borneol and menthol is alkaline, and the acidic substances in the herba violae can be neutralized, so that the overall Ph of the agent A and the agent B is more suitable for the cell growth, the influence of the agent A on the acidic and alkaline environment in a nasal cavity after the drug is taken is reduced, the repair of nasal mucosa cells is facilitated, and the curative effect of the drug is improved.
The borneol and the menthol act on nasal mucosa, have the effects of cooling and relieving itching, can relieve discomfort and stimulation of medication on the nasal mucosa, improve the medication acceptance of patients, refresh and restore consciousness, keep the brain clear, and relieve adverse symptoms such as hypomnesis and the like caused by rhinitis.
The preparation A is firstly used for nasal administration to promote the separation of thick nasal discharge in nasal cavity and effectively treat rhinitis, and the preparation B is then used for nasal administration to human body to repair damaged nasal mucosa, improve human body immunity and prevent rhinitis from recurring again, thus having good curative effect on rhinitis.
Preferably, the agent A comprises the following raw materials in parts by weight: 10 parts of cocklebur fruit, 15 parts of centipeda minima, 10 parts of magnolia flower, 5 parts of ligusticum chuanxiong hort, 5 parts of angelica dahurica, 3 parts of asarum, 7 parts of Chinese violet, 15 parts of wild chrysanthemum flower, 1 part of musk, 1 part of saffron, 8 parts of indigo naturalis, 5 parts of borneol and 5 parts of menthol;
the agent B comprises the following components in parts by weight: 15 parts of garden burnet root, 15 parts of Chinese violet, 20 parts of cotton rose hibiscus leaf, 10 parts of centipeda minima leaf, 10 parts of wild chrysanthemum flower, 5 parts of menthol, 5 parts of borneol, 5 parts of ligusticum chuanxiong hort and 1 part of musk.
By adopting the technical scheme and the raw material proportion, the formula has better curative effect.
In a second aspect, the application provides a preparation method of a nasal obstruction gel, which adopts the following technical scheme:
a preparation method of a Bitong gel comprises the following steps:
s1. preparation of an agent: mixing the raw materials of the preparation A under stirring, decocting in water for 1.5-2 hr, filtering to obtain filtrate, decocting the residue in water for 1.5-2 hr, repeating for 2-3 times, mixing filtrates, concentrating, and cooling to obtain concentrated solution of the preparation A;
weighing gel matrix, uniformly dispersing in distilled water, soaking until swelling completely, adding the concentrated solution of the preparation A, sequentially adding glycerol and antiseptic, stirring, dropwise adding triethanolamine until pH is 6.0-6.5, and stirring to obtain preparation A;
s2.B agent preparation: mixing the raw materials of the preparation B under stirring, decocting in water for 1.5-2 hr, filtering to obtain filtrate, decocting the residue in water for 1.5-2 hr, repeating for 2-3 times, mixing filtrates, concentrating, and cooling to obtain concentrated solution of preparation B;
weighing gel matrix, uniformly dispersing in distilled water, soaking until swelling completely, adding the concentrated solution of the preparation B, sequentially adding glycerol and antiseptic, stirring, dropwise adding triethanolamine until pH is 6.0-6.5, and stirring to obtain preparation B.
By adopting the technical scheme, the viola philippica contains active ingredients such as phytosterol, the active ingredients such as the phytosterol are dispersed in water after decoction, the saffron contains crocin which has the effects of anti-inflammation, antioxidation, antianaphylaxis and the like, can inhibit the breeding of bacteria and viruses in nasal cavities, and reduce anaphylactic reaction caused by medication, the sanguisorba officinalis contains sanguisorbin which has the effects of contracting blood vessels, stopping bleeding and resisting fungi and can promote the healing of damaged parts of nasal mucosa, the sanguisorbin and the crocin have good compatibility with the phytosterol, and after decoction, the phytosterol in the water can extract more sanguisorbin and crocin into the water, so that the content of the active ingredients such as the sanguisorbin and the crocin in the water is improved, and the effects of the A agent and the B agent are favorably improved.
Preferably, in S1, the cocklebur fruit is pre-fried at 70-80 ℃ until the color turns brown, for use.
By adopting the technical scheme, the cocklebur fruit is fried at high temperature and then used as a medicine, so that the toxicity of the cocklebur fruit can be reduced, and the adverse reaction of a human body after the medicine is taken can be relieved.
Preferably, the gel matrix is carbomer.
By adopting the technical scheme, the stimulation of the medicine to the nasal mucosa can be reduced by adopting carbomer, and the allergic reaction of the nasal mucosa can be favorably relieved.
Preferably, the mass ratio of the raw materials of the agent A, the gel matrix, the distilled water, the glycerol and the preservative is (18-20): (0.8-1): (14-16): (3-4): (0.1-0.2), the mass ratio of the raw materials of the B agent, the gel matrix, the distilled water, the glycerol and the preservative is (18-20): (0.8-1): (14-16): (3-4): (0.1-0.2).
By adopting the technical scheme and the raw material proportion, the nasal obstruction gel has proper viscosity, is convenient to take medicine, can be adhered to nasal mucosa and is not easy to slip, and is favorable for the nasal obstruction gel to exert the drug effect.
Preferably, the amount of water added during decocting with water is 10 times of the total weight of the raw materials.
In summary, the present application has the following beneficial effects:
1. the application adopts the A agent and the B agent to carry out administration on a patient in times, the A agent effectively treats rhinitis, the B agent improves the immunity of the patient, repairs damaged nasal mucosa, prevents rhinitis from relapsing again, has better curative effect and is difficult to relapse in the later period.
2. Through the fractional administration, the influence of toxic medicinal materials such as cocklebur fruit and the like in the A preparation on a human body is reduced, so that the toxic and side effects of the medicine on a patient are reduced, a better enhancement effect is favorably achieved, and the prevention of the relapse of rhinitis is facilitated.
3. The traditional Chinese medicines generate synergistic effect and supplement each other, so that the physical quality of the patient is improved, the resistance of the patient to other diseases is further improved, the patient is not easily affected by diseases such as wind cold and the like, and the probability of rhinitis recurrence caused by other diseases is reduced.
4. The administration process is mild, the nasal cavity of the patient is less stimulated, discomfort of the patient in the treatment process is reduced, and the nasal cavity is more easily accepted by the patient.
Detailed Description
The present application will be described in further detail with reference to examples.
Carbomer is adopted as the gel matrix in the application, carbomer 940 is adopted as the carbomer, and ethylparaben is adopted as the preservative.
The raw materials used in the following embodiments may be those conventionally commercially available unless otherwise specified.
Application method of Bitong gel
Applying the preparation A to nasal cavity of patient, covering nasal cavity with medical absorbent cotton, taking out medical cotton after 10min, and flushing nasal cavity with clear water once a day for one treatment period of two weeks.
After the treatment of the A preparation is finished, the B preparation is smeared in the nasal cavity of a patient, and the nasal wings on both sides are massaged for 3min, once a day, and the treatment lasts for one period, which is two weeks.
It is noted that a complete treatment cycle is four weeks as referred to in this application.
Examples
Example 1
The application discloses a nose-clearing gel, which comprises an agent A and an agent B, wherein the agent A comprises the following raw materials in parts by weight: 5 parts of cocklebur fruit, 15 parts of centipeda minima, 8 parts of biond magnolia flower, 6 parts of ligusticum chuanxiong hort, 6 parts of angelica dahurica, 3 parts of asarum, 6 parts of Chinese violet, 15 parts of wild chrysanthemum flower, 1 part of musk, 1 part of saffron crocus, 8 parts of indigo naturalis, 6 parts of borneol and 6 parts of menthol.
The agent B comprises the following raw materials in parts by weight: 15 parts of garden burnet root, 15 parts of Chinese violet, 25 parts of cotton rose hibiscus leaf, 12 parts of centipeda minima leaf, 10 parts of wild chrysanthemum flower, 4 parts of menthol, 4 parts of borneol, 4 parts of ligusticum chuanxiong hort and 1 part of musk.
The preparation method of the Bitong gel comprises the following steps:
s1. preparation of an agent: parching fructus Xanthii at 70 deg.C to brown, stirring and mixing agent A, adding 10 times of water, decocting for 1.5 hr, filtering to obtain filtrate, adding 10 times of water into residue, decocting for 1.5 hr, repeating for 3 times, mixing filtrates, concentrating filtrate to 1/15, cooling, and making into concentrated solution of agent A;
weighing gel matrix, uniformly dispersing in distilled water, soaking until swelling completely, adding the concentrated solution of the agent B, sequentially adding glycerol and antiseptic, stirring, dropwise adding triethanolamine while stirring until pH is 6.0, and stirring to obtain agent A;
s2.B agent preparation: mixing the raw materials of the preparation B, stirring, adding 10 times of water, decocting for 1.5h, filtering to obtain filtrate, adding 10 times of water into the residue, decocting for 1.5h, repeating for 3 times, mixing the filtrates, concentrating the filtrate to 1/15, cooling, and making into concentrate of preparation B;
weighing gel matrix, uniformly dispersing in distilled water, soaking until swelling completely, adding the concentrated solution of the preparation A, sequentially adding glycerol and antiseptic, stirring, dropwise adding triethanolamine while stirring until pH is 6.0, and stirring to obtain preparation B.
In the agent A, the mass ratio of raw materials, gel matrix, distilled water, glycerin and preservative is 18: 1: 14: 3: 0.1.
in the agent B, the mass ratio of the raw materials, the gel matrix, the distilled water, the glycerol and the preservative is 18: 1: 14: 3: 0.1.
example 2
The application discloses a nose-clearing gel, which comprises an agent A and an agent B, wherein the agent A comprises the following raw materials: 10 parts of cocklebur fruit, 10 parts of centipeda minima, 8 parts of biond magnolia flower, 4 parts of szechuan lovage rhizome, 4 parts of dahurian angelica root, 1 part of manchurian wildginger, 10 parts of philippine violet herb, 18 parts of wild chrysanthemum flower, 2 parts of musk, 2 parts of saffron crocus, 10 parts of natural indigo, 4 parts of borneol and 4 parts of menthol.
The agent B comprises the following raw materials: 12 parts of garden burnet root, 20 parts of Chinese violet, 20 parts of cotton rose hibiscus leaf, 10 parts of centipeda minima leaf, 8 parts of wild chrysanthemum flower, 6 parts of menthol, 6 parts of borneol, 6 parts of ligusticum chuanxiong hort and 2 parts of musk.
The preparation method of the Bitong gel comprises the following steps:
s1. preparation of an agent: parching fructus Xanthii at 80 deg.C to brown, mixing A preparation with stirring, adding 10 times of water, decocting for 2 hr, filtering to obtain filtrate, adding 10 times of water into the residue, decocting for 2 hr, repeating for 2 times, mixing filtrates, concentrating to 1/15, cooling, and making into A preparation concentrate;
weighing gel matrix, uniformly dispersing in distilled water, soaking until swelling completely, adding the concentrated solution of the preparation A, sequentially adding glycerol and antiseptic, stirring, dropwise adding triethanolamine while stirring until pH is 6.5, and stirring to obtain preparation A;
s2.B agent preparation: mixing the raw materials of the agent B, stirring, adding 10 times of water, decocting for 2h, filtering to obtain filtrate, adding 10 times of water into the residue, decocting for 2h, repeating for 2 times, mixing filtrates, concentrating the filtrate to 1/15, cooling, and making into concentrated solution of the agent B;
weighing gel matrix, uniformly dispersing in distilled water, soaking until swelling completely, adding the concentrated solution of the preparation B, sequentially adding glycerol and antiseptic, stirring, dropwise adding triethanolamine while stirring until pH is 6.5, and stirring to obtain preparation B.
In the agent A, the mass ratio of raw materials, gel matrix, distilled water, glycerin and preservative is 20: 1: 16: 3: 0.2.
in the agent B, the mass ratio of the raw materials, the gel matrix, the distilled water, the glycerol and the preservative is 20: 1: 16: 3: 0.2.
example 3
The application discloses a nose-clearing gel, which comprises an agent A and an agent B, wherein the agent A comprises the following raw materials in parts by weight: 10 parts of cocklebur fruit, 15 parts of centipeda minima, 10 parts of magnolia flower, 5 parts of ligusticum chuanxiong hort, 5 parts of angelica dahurica, 3 parts of asarum, 7 parts of Chinese violet, 15 parts of wild chrysanthemum flower, 1 part of musk, 1 part of saffron, 8 parts of indigo naturalis, 5 parts of borneol and 5 parts of menthol, wherein the cocklebur fruit is fried at 80 ℃ until the color turns to yellow for later use;
the agent B comprises the following components in parts by weight: 15 parts of garden burnet root, 15 parts of Chinese violet, 20 parts of cotton rose hibiscus leaf, 10 parts of centipeda minima leaf, 10 parts of wild chrysanthemum flower, 5 parts of menthol, 5 parts of borneol, 5 parts of ligusticum chuanxiong hort and 1 part of musk.
The preparation method of the Bitong gel comprises the following steps:
s1. preparation of an agent: parching fructus Xanthii at 75 deg.C to brown, mixing A preparation with stirring, adding 10 times of water, decocting for 2 hr, filtering to obtain filtrate, adding 10 times of water into the residue, decocting for 2 hr, repeating for 2 times, mixing filtrates, concentrating to 1/15, cooling, and making into A preparation concentrate;
weighing gel matrix, uniformly dispersing in distilled water, soaking until swelling completely, adding the concentrated solution of the preparation A, sequentially adding glycerol and antiseptic, stirring, dropwise adding triethanolamine while stirring until pH is 6.3, and stirring to obtain preparation A;
s2.B agent preparation: mixing the raw materials of the agent B, stirring, adding 10 times of water, decocting for 2h, filtering to obtain filtrate, adding 10 times of water into the residue, decocting for 2h, repeating for 2 times, mixing filtrates, concentrating the filtrate to 1/15, cooling, and making into concentrated solution of the agent B;
weighing gel matrix, uniformly dispersing in distilled water, soaking until swelling completely, adding the concentrated solution of the preparation B, sequentially adding glycerol and antiseptic, stirring, dropwise adding triethanolamine while stirring until pH is 6.3, and stirring to obtain preparation B.
In the agent A, the mass ratio of raw materials, gel matrix, distilled water, glycerol and preservative is 19: 0.8: 14: 4: 0.2.
in the agent B, the mass ratio of the raw materials, the gel matrix, the distilled water, the glycerol and the preservative is 19: 0.8: 14: 4: 0.2.
clinical trial
Three trial groups were set up, 100 patients were randomly selected for each trial group, of which:
10 male patients and 10 female patients with the age range of 10-20 years old respectively;
10 male patients and 10 female patients with age range of 21-30 years old respectively;
10 male patients and 10 female patients in the age range of 31-40 years old respectively;
10 male patients and 10 female patients in age range of 51-60 years old respectively;
10 male patients and 10 female patients in age range of 51-60 years old respectively.
Three test groups were treated with the nasal passage gel prepared in examples 1-3, and three months later, the specific treatment effects were reviewed by telephone call, see table 1.
TABLE 1 test results of the examples
Show effect Is effective Invalidation High efficiency Recurrence of disease Recurrence rate
Example 1 92 95 4 95% 5 5%
Example 2 94 96 2 96% 5 5%
Example 3 94 98 2 98% 4 4%
The effect is shown: rhinitis symptoms are all relieved
The method has the following advantages: partial relief of rhinitis symptoms
And (4) invalidation: rhinitis symptom has no any relief
Effective rate = (effective number of people/number of test people) × 100%
Recurrence rate = (number of relapsers/number of trials) × 100%
Clinical examples
Using the nasal passage gel prepared in example 1:
zhangqi, women, 52 years old, Putuoshan people in Zhoushan city, and the patients are diagnosed in 2018, 4 months and 20 days, and the symptoms are as follows: the nasal obstruction and the nasal discharge are 3 months, after one complete cycle of treatment, the nasal cavity is smooth and has no nasal discharge, and the recurrence is avoided after the three months of reexamination.
Forest, male, age 36, taizhou bank staff, visit 6, month 8 in 2018, symptoms: after the nasal obstruction is more than half a year, the nasal cavity is unobstructed after one complete cycle of treatment, and the nasal obstruction is rechecked for three months without relapse.
Using the nasal passage gel prepared in example 2:
zhouqi, male, 43 years old, house wenzhou Longwan, visit 2018 in 4 months and 27 days, with symptoms: nasal obstruction, running nose and smell which can not be identified in nearly three years, and after one complete cycle of treatment, the nasal cavity is unobstructed, no running nose exists, and no recurrence exists after three months of reexamination.
Using the nasal passage gel prepared in example 3:
wangzhi, women, 37 years old, warm ridge people, visit 7/6/2019, and have symptoms: the nasal obstruction lasts 8 months, after one complete cycle of treatment, the nasal cavity is unobstructed, and after three months, the nasal obstruction is rechecked without relapse.
Suzhong, male, 15 years old, home in the district of Nazhou Longwan, visit 7/6/2020, symptoms: nasal obstruction, sneezing for more than half a year, after one complete cycle of treatment, the nasal cavity is unobstructed, and no recurrence is asked after three months.
In addition, 500 patients who apply the nasal obstruction gel therapy for years are randomly selected, and the statistical result shows that the effective rate of the therapy reaches more than 95 percent, and the recurrence rate is lower than 10 percent.
The present embodiment is only for explaining the present application, and it is not limited to the present application, and those skilled in the art can make modifications of the present embodiment without inventive contribution as needed after reading the present specification, but all of them are protected by patent law within the scope of the claims of the present application.

Claims (7)

1. The nose-clearing gel is characterized by comprising an agent A and an agent B, wherein the agent A comprises the following raw materials in parts by weight: 5-10 parts of cocklebur fruit, 10-15 parts of centipeda minima, 8-10 parts of biond magnolia flower, 4-6 parts of ligusticum chuanxiong hort, 4-6 parts of angelica dahurica, 1-3 parts of asarum, 6-10 parts of Chinese violet, 10-15 parts of wild chrysanthemum flower, 4-6 parts of borneol, 4-6 parts of menthol, 1-2 parts of musk, 1-2 parts of saffron crocus and 8-10 parts of indigo naturalis;
the agent B comprises the following raw materials in parts by weight: 12-15 parts of garden burnet root, 15-20 parts of Chinese violet, 20-25 parts of cotton rose hibiscus leaf, 10-12 parts of centipeda minima leaf, 8-10 parts of wild chrysanthemum flower, 4-6 parts of ligusticum chuanxiong hort, 4-6 parts of borneol, 4-6 parts of menthol and 1-2 parts of musk;
the application method of the nasal obstruction gel comprises the following steps: applying the A preparation to nasal cavity of patient for a period of treatment; after the treatment of the A preparation is finished, the B preparation is smeared in the nasal cavity of a patient and is treated for one cycle.
2. The nasal passage gel of claim 2, wherein: the agent A comprises the following raw materials in parts by weight: 10 parts of cocklebur fruit, 15 parts of centipeda minima, 10 parts of magnolia flower, 5 parts of ligusticum chuanxiong hort, 5 parts of angelica dahurica, 3 parts of asarum, 7 parts of Chinese violet, 15 parts of wild chrysanthemum flower, 1 part of musk, 1 part of saffron, 8 parts of indigo naturalis, 5 parts of borneol and 5 parts of menthol;
the agent B comprises the following components in parts by weight: 15 parts of garden burnet root, 15 parts of Chinese violet, 20 parts of cotton rose hibiscus leaf, 10 parts of centipeda minima leaf, 10 parts of wild chrysanthemum flower, 5 parts of menthol, 5 parts of borneol, 5 parts of ligusticum chuanxiong hort and 1 part of musk.
3. A method for preparing a bitong gel according to claim 1 or 2, wherein the method comprises the steps of: the method comprises the following steps:
s1. preparation of an agent: mixing the raw materials of the preparation A under stirring, decocting in water for 1.5-2 hr, filtering to obtain filtrate, decocting the residue in water for 1.5-2 hr, repeating for 2-3 times, mixing filtrates, concentrating, and cooling to obtain concentrated solution of the preparation A;
weighing gel matrix, uniformly dispersing in distilled water, soaking until swelling completely, adding the concentrated solution of the preparation A, sequentially adding glycerol and antiseptic, stirring, dropwise adding triethanolamine until pH is 6.0-6.5, and stirring to obtain preparation A;
s2.B agent preparation: mixing the raw materials of the preparation B under stirring, decocting in water for 1.5-2 hr, filtering to obtain filtrate, decocting the residue in water for 1.5-2 hr, repeating for 2-3 times, mixing filtrates, concentrating, and cooling to obtain concentrated solution of preparation B;
weighing gel matrix, uniformly dispersing in distilled water, soaking until swelling completely, adding the concentrated solution of the preparation B, sequentially adding glycerol and antiseptic, stirring, dropwise adding triethanolamine until pH is 6.0-6.5, and stirring to obtain preparation B.
4. The method for preparing a bitong gel according to claim 3, wherein: in the step S1, the cocklebur fruit is fried at 70-80 ℃ in advance until the color turns to brown for later use.
5. The method for preparing a bitong gel according to claim 3, wherein: the gel matrix is carbomer.
6. The method for preparing a bitong gel according to claim 3, wherein: the mass ratio of the raw materials of the agent A, the gel matrix, the distilled water, the glycerol and the preservative is (18-20): (0.8-1): (14-16): (3-4): (0.1-0.2), the mass ratio of the raw materials of the B agent, the gel matrix, the distilled water, the glycerol and the preservative is (18-20): (0.8-1): (14-16): (3-4): (0.1-0.2).
7. The method for preparing a bitong gel according to claim 3, wherein: the amount of water added during decocting is 10 times of the total weight of the raw materials.
CN202111145139.1A 2021-09-28 2021-09-28 Bitong gel and using method and preparation method thereof Pending CN113730341A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111145139.1A CN113730341A (en) 2021-09-28 2021-09-28 Bitong gel and using method and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111145139.1A CN113730341A (en) 2021-09-28 2021-09-28 Bitong gel and using method and preparation method thereof

Publications (1)

Publication Number Publication Date
CN113730341A true CN113730341A (en) 2021-12-03

Family

ID=78741602

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111145139.1A Pending CN113730341A (en) 2021-09-28 2021-09-28 Bitong gel and using method and preparation method thereof

Country Status (1)

Country Link
CN (1) CN113730341A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114984122A (en) * 2022-05-30 2022-09-02 袁庆堂 Traditional Chinese medicine ointment for treating acute and chronic rhinitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107233416A (en) * 2016-03-24 2017-10-10 中超科技（大连）有限公司 Rhinitis ointment for nasal membrane inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107233416A (en) * 2016-03-24 2017-10-10 中超科技（大连）有限公司 Rhinitis ointment for nasal membrane inflammation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114984122A (en) * 2022-05-30 2022-09-02 袁庆堂 Traditional Chinese medicine ointment for treating acute and chronic rhinitis

Similar Documents

Publication Publication Date Title
CN106177408B (en) Skin anti-allergy traditional Chinese medicine composition, traditional Chinese medicine preparation, mask and preparation method
CN103751310A (en) External traditional Chinese medicinal preparation for treating fasciitis and preparation method thereof
CN113730341A (en) Bitong gel and using method and preparation method thereof
CN112915173A (en) Traditional Chinese medicine composition for treating orthopedic diseases, preparation method and application
CN106421392A (en) Traditional Chinese medicinal gel for treating bedsore and preparation method of traditional Chinese medicinal gel
CN102106920B (en) Chinese medicinal composition for treating burn and scald and application thereof
CN108159360B (en) Traditional Chinese medicine hoof care cream for cow hoof injury and preparation method thereof
CN113082089A (en) Traditional Chinese medicine ointment for treating skin allergy and preparation method thereof
CN105031170A (en) Healthcare foot bath powder and preparing method thereof
CN112972578A (en) Ointment for treating psoriasis and preparation method thereof
CN105853866A (en) Method for preparing Chinese herbal medicine composition for treating bedsore
CN112691170B (en) Traditional Chinese medicine composition for treating alopecia and application thereof
CN116115687B (en) Traditional Chinese medicine composition for gout and preparation method and application thereof
CN115192689B (en) Traditional Chinese medicine composition for treating neck, shoulder, waist and leg pain, application and traditional Chinese medicine preparation thereof
CN111358927B (en) Pujiang medicinal composition and application thereof
JPS5813518A (en) Preparation of drug consisting of ganoderma lucidum and elfvingia applanata
CN105535853A (en) Traditional Chinese medicine composition for treating bedsores for clinical nursing
CN108210596B (en) Traditional Chinese medicine for reducing blood pressure and method for preparing plaster for reducing blood pressure by using traditional Chinese medicine
CN105456718A (en) Medicinal extract for curing radiodermatitis and preparation thereof
CN111298038A (en) External washing traditional Chinese medicine composition for treating vulvitis and preparation method thereof
CN105193996A (en) Traditional Chinese medicine composition for treating decubitus and preparation method of traditional Chinese medicine composition
CN114796337A (en) Compound phellodendron bark preparation and application thereof
CN112870301A (en) Scar repairing essence and preparation method and application thereof
CN117771166A (en) Traditional Chinese medicine ointment for treating targeted drug-related rash as well as preparation method and application thereof
CN113082090A (en) Traditional Chinese medicine care solution for improving skin allergy and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination